Status:
COMPLETED
An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Lymphoma, B-Cell, Lymphoma, Follicular
Eligibility:
All Genders
18+ years
Brief Summary
This observational study aims to assess the therapeutic responsiveness of MabThera SC in patients with malignant lymphomas under everyday clinical practice conditions. Patients with previously untreat...
Eligibility Criteria
Inclusion
- Women and men aged \>=18 years
- Previously untreated CD-20 positive follicular NHL
- Previously untreated CD-20 positive DLBCL
- Planned therapy with MabThera SC according to the assessment of the physician (before the start and independent from this study)
- Suitability for the therapy with MabThera SC
Exclusion
- All contraindications, interactions and incompatibilities for therapy with MabThera SC
Key Trial Info
Start Date :
July 8 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 22 2019
Estimated Enrollment :
688 Patients enrolled
Trial Details
Trial ID
NCT02240316
Start Date
July 8 2014
End Date
July 22 2019
Last Update
October 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Essen; Klinik für Hämatologie
Essen, Germany, 45122